3-(4-chlorophenyl)-3-hydroxypyrrolidine | 154956-79-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 3-(4-chlorophenyl)-3-hydroxypyrrolidine
• 英文别名: 3-Hydroxy-3-<4-chlor-phenyl>-pyrrolidin；3-(4-Chlorphenyl)-3-pyrrolidinol；3-Hydroxy-3-(4-chlor-phenyl)-pyrrolidin；3-(4-chloro-phenyl)-pyrrolidin-3-ol；3-hydroxy-3-(4'-chlorophenyl)pyrrolidine；3-(4-chlorophenyl)-3-hydroxypyrolidine；3-(4-Chlorophenyl)pyrrolidin-3-ol
• CAS: 154956-79-3
• 化学式: C₁₀H₁₂ClNO
• 分子量: 197.664
• InChiKey: CAVQGCMJFBZRLQ-UHFFFAOYSA-N

物化性质

• 沸点：
  340.7±42.0 °C(Predicted)
• 密度：
  1.264±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(2-溴乙基)吲哚 、 3-(4-chlorophenyl)-3-hydroxypyrrolidine 在 碳酸氢钠 作用下， 以 乙腈 为溶剂， 反应 4.0h， 以22%的产率得到3-(4-chlorophenyl)-1-[2-(1H-indol-3-yl)ethyl]pyrrolidin-3-ol
  参考文献：
  名称：

  Synthesis and evaluation of ligands for D2-like receptors: The role of common pharmacophoric groups

  摘要：

  Arylcycloalkylamines, such as phenyl piperidines and piperazines and their arylalkyl substituents, constitute pharmacophoric groups exemplified in several antipsychotic agents. A review of previous reports indicates that arylalkyl substituents can improve the potency and selectivity of the binding affinity at D-2-like receptors. In this paper, we explored the contributions of two key pharmacophoric groups, that is, 40-fluorobutyrophenones and 3-methyl-7-azaindoles, to the potency and selectivity of synthesized agents at D-2-like receptors. Preliminary observation of binding affinities indicates that there is little predictability of specific effects of the arylalkyl moieties but the composite structure is responsible for selectivity and potency at these receptors. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmc.2008.12.054
• 作为产物：
  描述：

  3-(4-chloro-phenyl)-3-hydroxy-pyrrolidine-1-carboxylic acid ethyl ester 在 氢氧化钾 作用下， 以 乙醇 、 水 为溶剂， 反应 12.0h， 以84.6%的产率得到3-(4-chlorophenyl)-3-hydroxypyrrolidine
  参考文献：
  名称：

  Haloperidol analogs

  摘要：

  氟哌啶酮类似物符合以下结构式：其中：R为H，或—(CH2)n—OH，n为0至2的整数，且A为杂环桥接基团，主要由碳和至少一个氮原子组成，有效地保持连接的基团之间的距离，使得化合物（1）无法代谢为BCPP+类似物，具有对D2受体亚型的亲和力15

  公开号：

  US20060052363A1

文献信息

• CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20160031908A1

  公开（公告）日：2016-02-04

  Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.

  揭示了新颖的化合物以及治疗与异常白细胞召集和/或激活相关的疾病的方法。该方法包括向需要的受试者施用代表的化合物的有效量： 或其生理上可接受的盐。
• Chemokine receptor anagonists and methods of use therefor
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20020169155A1

  公开（公告）日：2002-11-14

  Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: 1 or physiologically acceptable salt thereof.

  揭示了新颖的化合物以及一种治疗与异常白细胞召集和/或激活相关疾病的方法。该方法包括向需要的受试者施用化合物1或其生理上可接受的盐的有效量。
• CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR
  申请人：——

  公开号：US20020119973A1

  公开（公告）日：2002-08-29

  Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: 1 and physiologically acceptable salts thereof. 2

  披露了新颖的化合物以及一种治疗与异常白细胞招募和/或激活相关疾病的方法。该方法包括向需要治疗的主体施用一种有效量的化合物，该化合物由以下结构表示： 1 以及它们的生理可接受的盐。 2
• Chemokine receptor antagonists and methods of use thereof
  申请人：Luly R. Jay

  公开号：US20050070549A1

  公开（公告）日：2005-03-31

  Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: formula (1) or physiologically acceptable salt thereof.

  揭示了新化合物和一种治疗与异常白细胞召集和/或激活相关疾病的方法。该方法包括向需要的受试者施用由以下公式（1）表示的化合物或其生理上可接受的盐的有效量。
• NOVEL COMPOUNDS USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS
  申请人：KHAMRAI Uttam

  公开号：US20100168080A1

  公开（公告）日：2010-07-01

  The present invention relates to novel morpholine, oxazapane and piperidine derivatives that act as ligands for CC chemokine receptors, such as CCR1. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.

  本发明涉及作为CC趋化因子受体，如CCR1的配体的新型吗啉、恶唑烷和哌啶衍生物。该发明还涉及制备这些化合物的方法、包含这些化合物的组合物以及使用这些化合物的治疗方法。